Artigo de periodico

Bioactive lipids as chronic myeloid leukemia’s potential biomarkers for disease progression and response to tyrosine kinase inhibitors (2022)

• Authors:
  • Almeida, Felipe Campos de
  • Berzoti-Coelho, Maria Gabriela
  • Toro, Diana Mota
  • Cacemiro, Maira da Costa
  • Bassan, Vitor Leonardo
  • Barretto, Gabriel Dessotti
  • Garibaldi, Pedro Manoel Marques
  • Palma, Leonardo Carvalho
  • Pontes, Lorena Lobo de Figueiredo
  • Sorgi, Carlos Arterio
  • Faccioli, Lucia Helena
  • Gardinassi, Luiz Gustavo Araujo
  • Castro, Fabíola Attié de
• USP affiliated authors: CACEMIRO, MAIRA DA COSTA - FCFRP ; PALMA, LEONARDO CARVALHO - FMRP ; PONTES, LORENA LÔBO DE FIGUEIREDO - FMRP ; SORGI, CARLOS ARTERIO - FFCLRP ; FACCIOLI, LUCIA HELENA - FCFRP ; CASTRO, FABÍOLA ATTIÉ DE - FCFRP ; ALMEIDA, FELIPE CAMPOS DE - FCFRP ; COELHO, MARIA GABRIELA BERZOTI - IQ ; BASSAN, VITOR LEONARDO - FCFRP ; BARRETTO, GABRIEL DESSOTTI - FCFRP
• Unidades: FCFRP; FMRP; FFCLRP; IQ
• DOI: 10.3389/fimmu.2022.840173
• Subjects: BIOMARCADORES; NEOPLASIAS; LEUCEMIA MIELOIDE; FARMACOTERAPIA; PROTEÍNAS QUINASES
• Keywords: Chronic myeloid leukemia; Bioactive lipids; Tyrosine kinase inhibitors; Pathogenesis and metabolomics; Tyrosine kinasa inhibitor
• Agências de fomento:
  • Financiamento CNPq
  • Financiamento CAPES
  • Financiamento FAPESP
• Language: Inglês
• Imprenta:
  • Publisher place: Lausanne
  • Date published: 2022
• Source:
  • Título: Frontiers in Immunology
  • ISSN: 1664-3224
  • Volume/Número/Paginação/Ano: v. 13, art. 840173, p. 1-8, 2022


Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).

Status:

Artigo publicado em periódico de acesso aberto (Gold Open Access)

Versão do Documento:

Versão publicada (Published version)

Acessar versão aberta:

• PDF de acesso aberto

Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.

---

Download do texto completo

Tipo	Nome	Link
	003277044.pdf	Direct link

How to cite

A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

• ABNT

  ALMEIDA, Felipe Campos de et al. Bioactive lipids as chronic myeloid leukemia’s potential biomarkers for disease progression and response to tyrosine kinase inhibitors. Frontiers in Immunology, v. 13, p. 1-8, 2022Tradução . . Disponível em: https://doi.org/10.3389/fimmu.2022.840173. Acesso em: 09 maio 2026.

• APA

  Almeida, F. C. de, Berzoti-Coelho, M. G., Toro, D. M., Cacemiro, M. da C., Bassan, V. L., Barretto, G. D., et al. (2022). Bioactive lipids as chronic myeloid leukemia’s potential biomarkers for disease progression and response to tyrosine kinase inhibitors. Frontiers in Immunology, 13, 1-8. doi:10.3389/fimmu.2022.840173

• NLM

  Almeida FC de, Berzoti-Coelho MG, Toro DM, Cacemiro M da C, Bassan VL, Barretto GD, Garibaldi PMM, Palma LC, Pontes LL de F, Sorgi CA, Faccioli LH, Gardinassi LGA, Castro FA de. Bioactive lipids as chronic myeloid leukemia’s potential biomarkers for disease progression and response to tyrosine kinase inhibitors [Internet]. Frontiers in Immunology. 2022 ; 13 1-8.[citado 2026 maio 09 ] Available from: https://doi.org/10.3389/fimmu.2022.840173

• Vancouver

  Almeida FC de, Berzoti-Coelho MG, Toro DM, Cacemiro M da C, Bassan VL, Barretto GD, Garibaldi PMM, Palma LC, Pontes LL de F, Sorgi CA, Faccioli LH, Gardinassi LGA, Castro FA de. Bioactive lipids as chronic myeloid leukemia’s potential biomarkers for disease progression and response to tyrosine kinase inhibitors [Internet]. Frontiers in Immunology. 2022 ; 13 1-8.[citado 2026 maio 09 ] Available from: https://doi.org/10.3389/fimmu.2022.840173

Últimas obras dos mesmos autores vinculados com a USP cadastradas na BDPI:

• Kinetics of BCR::ABL1 transcript levels and molecular relapse after tyrosine kinase inhibitors discontinuation in chronic myeloid leukemia patients: preliminary results from the DES-CML study
• Arachidonic acid (aa)-derived lipid mediators are increased in the bone marrow plasma from polycythemia vera and essential thrombocythemia patients
• Deregulation of bone marrow eicosanoids in essential thrombocythemia and primary myelofibrosis patients
• Immunophenotypic profiling reveals altered expression of platelet activation markers in patients with myeloproliferative neoplasms
• Philadelphia-negative myeloproliferative neoplasms display alterations in monocyte subpopulations frequency and immunophenotype
• Migration of the eosinophil and mononuclear cell numbers to bronchoalveolar fluid peritoneal cavity inteleukin-12 knockout and C57BL/9 mice infected by Strongyloides venezuelensis
• Prostaglandins inhibits immune response in histoplamosis
• 5-LO, FLAP, and BLT1 expression in human T cell lymphotropic virus type 1
• The role of 'beta'-2 integrin in alveolar macrophage phagocytic activity in histoplasmosis
• Role of 5-lipoxigenase on lipid body formation induced by Histoplasma capsulatum cell wall 'beta'-glucan and coinfected immunity